Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing apabetalone (RVX-208), a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimer s disease, and orphan diseases. Resverlogix Corp. is headquartered in Calgary, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for RVXCF